Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma | Citedby Results | Cancer Discovery | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

Cancer Discov (2019) 9 (11): 1629.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Neeraj Jain
Mukesh Mamgain
Sayan Mullick Chowdhury
Udita Jindal
Isha Sharma
Lalit Sehgal
Narendranath Epperla

Journal of Hematology & Oncology (2023) 16 (1)

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance

Shan-Liang Sun
Shi-Han Wu
Ji-Bo Kang
Yi-Yuan Ma
Lu Chen
Peng Cao
Liang Chang
Ning Ding
Xin Xue
Nian-Guang Li
Zhi-Hao Shi

Journal of Medicinal Chemistry (2022) 65 (11): 7415.